More than 1,000 eye care professionals worldwide have been using the AdaptDx® and AdaptDx Pro® to test for impaired dark adaptation, the earliest biomarker of age-related macular degeneration. Our customers tell the story of how they’re fighting against preventable blindness by identifying AMD at its earliest stages and closely monitoring its progression.
Since implementing the AMD Excellence Program and performing AdaptDx Pro Rapid Tests on every patient over 60, I can confirm that the studies are true: 25-30% of my patients are failing. By practicing this way, I can confidently say I have more AMD patients than glaucoma and diabetic retinopathy combined, and it will only continue to grow. Luckily, our team is up to the challenge and is excited to contribute to an improved standard of AMD care for our patients!